These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 30108109)

  • 1. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.
    Jaglowski SM; Blazar BR
    Blood Adv; 2018 Aug; 2(15):2012-2019. PubMed ID: 30108109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrutinib for the treatment of patients with chronic graft-versus-host disease after failure of one or more lines of systemic therapy.
    Rahmat LT; Logan AC
    Drugs Today (Barc); 2018 May; 54(5):305-313. PubMed ID: 29911695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice.
    Schutt SD; Fu J; Nguyen H; Bastian D; Heinrichs J; Wu Y; Liu C; McDonald DG; Pidala J; Yu XZ
    PLoS One; 2015; 10(9):e0137641. PubMed ID: 26348529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
    Miklos D; Cutler CS; Arora M; Waller EK; Jagasia M; Pusic I; Flowers ME; Logan AC; Nakamura R; Blazar BR; Li Y; Chang S; Lal I; Dubovsky J; James DF; Styles L; Jaglowski S
    Blood; 2017 Nov; 130(21):2243-2250. PubMed ID: 28924018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
    Doki N; Toyosaki M; Shiratori S; Osumi T; Okada M; Kawakita T; Sawa M; Ishikawa T; Ueda Y; Yoshinari N; Nakahara S
    Transplant Cell Ther; 2021 Oct; 27(10):867.e1-867.e9. PubMed ID: 34102349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.
    Dubovsky JA; Flynn R; Du J; Harrington BK; Zhong Y; Kaffenberger B; Yang C; Towns WH; Lehman A; Johnson AJ; Muthusamy N; Devine SM; Jaglowski S; Serody JS; Murphy WJ; Munn DH; Luznik L; Hill GR; Wong HK; MacDonald KK; Maillard I; Koreth J; Elias L; Cutler C; Soiffer RJ; Antin JH; Ritz J; Panoskaltsis-Mortari A; Byrd JC; Blazar BR
    J Clin Invest; 2014 Nov; 124(11):4867-76. PubMed ID: 25271622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host disease.
    King-Kallimanis BL; Wroblewski T; Kwitkowski V; De Claro RA; Gwise T; Bhatnagar V; Farrell AT; Kluetz PG
    Qual Life Res; 2020 Jul; 29(7):1903-1911. PubMed ID: 32100182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience.
    Chin KK; Kim HT; Inyang EA; Ho V; Koreth J; Romee R; Gooptu M; Shapiro R; Antin J; Soiffer R; Jaglowski S; Pidala J; Cutler C
    Transplant Cell Ther; 2021 Dec; 27(12):990.e1-990.e7. PubMed ID: 34481113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
    Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
    Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
    Waller EK; Miklos D; Cutler C; Arora M; Jagasia MH; Pusic I; Flowers MED; Logan AC; Nakamura R; Chang S; Clow F; Lal ID; Styles L; Jaglowski S
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2002-2007. PubMed ID: 31260802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three US Food and Drug Administration-approved therapies for chronic GVHD.
    Zeiser R; Lee SJ
    Blood; 2022 Mar; 139(11):1642-1645. PubMed ID: 35081254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease.
    Martini DJ; Chen YB; DeFilipp Z
    Oncologist; 2022 Aug; 27(8):685-693. PubMed ID: 35443042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant Ruxolitinib and Ibrutinib for Graft-Versus-Host Disease (GVHD): The First Reported Use in Pediatric Patients.
    Gagliardi TA; Milner J; Cairo MS; Steinberg A
    Cureus; 2022 Sep; 14(9):e29195. PubMed ID: 36258935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE Study.
    Carpenter PA; Kang HJ; Yoo KH; Zecca M; Cho B; Lucchini G; Nemecek ER; Schultz KR; Stepensky P; Chaudhury S; Oshrine B; Khaw SL; Harris AC; Verna M; Zubarovskaya L; Lee Y; Wahlstrom J; Styles L; Shaw PJ; Dalle JH
    Transplant Cell Ther; 2022 Nov; 28(11):771.e1-771.e10. PubMed ID: 36044977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Ibrutinib for Chronic Graft-Versus-Host Disease: A Systematic Review.
    Santosa D; Rizky D; Tandarto K; Kartiyani I; Yunarvika V; Ardini DNE; Setiawan B; Pangarsa EA; Suharti C
    Asian Pac J Cancer Prev; 2023 Dec; 24(12):4025-4033. PubMed ID: 38156834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
    Gonzalez RM; Pidala J
    Pharmacotherapy; 2020 Aug; 40(8):756-772. PubMed ID: 32441379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of rituximab in chronic graft-versus-host disease.
    Bates JS; Engemann AM; Hammond JM
    Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.
    Xue E; Lorentino F; Pavesi F; Assanelli A; Peccatori J; Bernardi M; Corti C; Ciceri F; Lupo Stanghellini MT
    Leuk Res; 2021 Oct; 109():106642. PubMed ID: 34157510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysis.
    Yu J; Lal LS; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
    Curr Med Res Opin; 2021 May; 37(5):755-759. PubMed ID: 33615925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease.
    Zeiser R
    J Clin Oncol; 2023 Apr; 41(10):1820-1824. PubMed ID: 36800551
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.